EVAXEvaxion Biotech A/SFinished
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
Melanoma Stage IV · Unresectable Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 17 (final count)
- Started
- Sep 19, 2022
- Main results expected
- Apr 7, 2026
- Fully finished
- Apr 7, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change in the best overall response (BOR)
Measured over: Measurements at Baseline through study completion (up to 102 weeks)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05309421 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC